|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Prostatic Hyperplasia | |||||
| Prostatic Hypertrophy, Benign | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Hyperplasia | |||||
| Hypertrophy | |||||
| 3 | More general conditions related to this trial | ||||
| Genital Diseases, Male | |||||
| Pathologic Processes | |||||
| Pathological Conditions, Anatomical | |||||
| Prostatic Diseases | |||||
| 4 | Interventions listed in this trial | ||||
| Doxazosin | |||||
| Finasteride | |||||
| 5 | More general drug interventions related to this trial | ||||
| Adrenergic Agents | |||||
| Adrenergic alpha-Antagonists | |||||
| Adrenergic Antagonists | |||||
| Antihypertensive Agents | |||||
| Cardiovascular Agents | |||||
| Enzyme Inhibitors | |||||
| Molecular Mechanisms of Pharmacological Action | |||||
| Neurotransmitter Agents | |||||
| Pharmacologic Actions | |||||
| Physiological Effects of Drugs | |||||
| Therapeutic Uses | |||||
| 6 | Sponsors listed in this trial | ||||
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | |||||